-

Meet with the OrganaBio executives in-person at The Cell & Gene Meeting on the Mesa

original Heading to Alliance for Regenerative Medicine's Meeting on the Mesa October 11-13? Join us for a few days to chat about how we can partner to scale-up and provide supply chain platforms for advanced therapies in a customizable way – one that’s tailored to your evolving needs. (Photo: OrganaBio, LLC)

Heading to Alliance for Regenerative Medicine's Meeting on the Mesa October 11-13? Join us for a few days to chat about how we can partner to scale-up and provide supply chain platforms for advanced therapies in a customizable way – one that’s tailored to your evolving needs. (Photo: OrganaBio, LLC)

MIAMI--(BUSINESS WIRE)--The 2022 Cell & Gene Meeting on the Mesa annual conference will be held in Carlsbad, California, on October 11-13, 2022, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. Meet with the OrganaBio team to learn about our reliable supply of high-quality, ethically sourced tissue and cellular raw materials with clear paths to clinical translation, and the advanced processing and characterization capabilities we offer to speed up novel therapeutic development.

OrganaBio’s CEO, Justin Irizarry, and VP of Corporate Development, Dr. Priya Baraniak, will join the over 1,700 attendees, and will be available for one-on-one meetings to discuss available solutions to cell therapy developers.

www.organabio.com

Contacts

Dr. Priya Baraniak
Vice President of Corporate Development
priya@organabio.com

Industry:

OrganaBio, LLC

Details
Headquarters: South Miami, FL
CEO: Justin Irizarry
Employees: 50
Organization: PRI
Release Versions
English
Hashtags
#biotech
#cellandgene
#cellandgenetherapy
#celltherapy
#cgmesa22
#clinicalpartnerships

Contacts

Dr. Priya Baraniak
Vice President of Corporate Development
priya@organabio.com

Social Media Profiles
OrganaBio Facebook
Meet Justin Irizarry, Chief Executive Officer
OrganaBio LinkedIn
Meet Dr. Priya Baraniak, VP Corporate Development
OrganaBio Twitter
More News From OrganaBio, LLC

OrganaBio Approved as A Science Exchange and Scientist.com Partner

MIAMI--(BUSINESS WIRE)--OrganaBio products and services can now be accessed via the Science Exchange and Scientist.com platforms. Both online marketplaces allow buyers to find and request services directly through the platform and help streamline communication and buying processes through standardized proposal and contracting mechanisms. Drug developers can now leverage www.scienceexchange.com and www.scientist.com and search for OrganaBio’s services and products specifically (e.g. donor screen...

GaiaGift Triples Physician Network to Ethically Collect Increasing Volumes of Birth Tissues Needed for the Rapidly Burgeoning Development of Cell and Gene Therapies

MIAMI--(BUSINESS WIRE)--GaiaGift, LLC (a wholly owned subsidiary of OrganaBio, LLC) a leader in the field of birth tissue collection, announces the expansion of its esteemed physician network, offering more opportunities for donors to participate in its remarkable donation program supporting the development of novel cell and gene therapies. GaiaGift's mission is to empower families to make a positive impact on healthcare by ethically donating otherwise discarded birth tissue, contributing to gr...

Introducing NeoPAC™ Tissues: OrganaBio Unveils New Birth Tissue Products to Advance Regenerative Medicine and Cell Therapy

SOUTH MIAMI, Fla.--(BUSINESS WIRE)--OrganaBio is thrilled to announce the launch of NeoPAC™ placenta and umbilical cord tissues, its latest suite of products designed to accelerate the progress of regenerative medicine and cell therapy. By offering both Research Use Only (RUO) and clinical (cGMP) grade tissues, OrganaBio empowers researchers to tap into the potential of birth tissues, enabling the development of innovative therapies to address a wide range of medical conditions. NeoPAC™ tissues...
Back to Newsroom